| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03388164 Details | 2021-09-16 Interventional | 2 | 23 | Citalopram Dexetimide Escitalopram Depression Depressive Diso… | The study was terminated early based on the planned interim analysis that did not meet criteria
for continuation. The study was terminated early based on the planned interim analysis. | |||
| NCT04745663 2019-001179-35 Details | 2021-09-14 Interventional | 4 | 150 | Cadexomer iodin… Iodine Povidone Povidone-Iodine Eye Infections | Not the expected 2/3 but only 1/3 of conjunctiva samples got bacterial growth. Lack of
resources to keep the study going with more participants and over a considerably longer time
than anticipated. - | |||
| NCT01899170 2013-002385-39 Details | 2021-09-14 Interventional | 2 | 3 | Carfentanil Neuralgia | Device for multi coil TMS no longer supported - | |||
| NCT04446637 Details | 2021-09-13 Interventional | 3 | 0 | Albuterol Ipratropium Lung Diseases Lung Diseases, … Pulmonary Disea… Chronic Obstruc… | administrative decision - | |||
| NCT01548144 Details | 2021-09-13 Interventional | 1 | 178 | Crizotinib Pemetrexed Neoplasms Advanced Cancer… | PI request - | |||
| NCT04322682 Details | 2021-09-08 Interventional | 3 | 4506 | Colchicine Coronavirus Inf… Corona Virus In… | Due to several considerations (logistical, human and budgetary), the study was stopped early. Due to several considerations (logistical, human and budgetary), the study was stopped early. Furthermore, stopping the study after approximately 4500 patients had completed their 30-day follow-up would allow to communicate results in January 2021 in the hope of preventing complications of COVID-19 in ambulatory patients, instead of delivering results anywhere between April and October 2021 at a time when vaccination efforts might be successful. | |||
| NCT03563040 2018-001685-42 Details | 2021-09-08 Interventional | 2 | 0 | Methoxsalen Lymphoma, T-Cel… Lymphoma, T-Cel… Mycoses Mycosis Fungoid… Sezary Syndrome Mycosis Fungoid… | Lack of feasibility - | |||
| NCT02959554 2016-002170-13 Details | 2021-09-08 Interventional | 2 | 49 | Nivolumab Sunitinib Carcinoma Carcinoma, Rena… Metastatic Rena… | - - | |||
| NCT03892889 Details | 2021-09-05 Interventional | 3 | 277 | Aripiprazole Schizophrenia | Study has stopped for having met the primary endpoint. - | |||
| NCT03806231 Details | 2021-09-05 Interventional | 3 | 8 | Dinoprostone Induction of La… | Sponsor declined to provide further funding/product support. Trial terminated prior to meeting sufficient sample size for outcome analyses. | |||
| NCT03608618 Details | 2021-09-05 Interventional | 1 | 14 | Cyclophosphamid… Adenocarcinoma Carcinoma, Ovar… Mesothelioma Mesothelioma, M… Adenocarcinoma … Fallopian Tube … Peritoneal Meso… Primary Periton… | Sponsor shift in focus - | |||
| NCT02851004 Details | 2021-09-05 Interventional | 1/2 | 55 | Pembrolizumab Colorectal Neop… Metastatic Colo… | On the request of the investigational drug provider. No subjects were newly enrolled in the
additional cohort as they were preparing to resume enrollment in the additional cohort.
Currently, it is preparing the creation of clinical study report. - | |||
| NCT02459613 Details | 2021-08-26 Interventional | 1/2 | 11 | Annexin A5 Endocarditis Thrombosis | - - | |||
| NCT03696342 Details | 2021-08-24 Interventional | 3 | 46 | Gatifloxacin Pazufloxacin Conjunctivitis Conjunctivitis,… | Sponsor's convenience This trial was terminated early due to the sponsor's convenience in the pipeline followed by the studied product. A small sample renders this results as merely descriptive. | |||
| NCT03545165 Details | 2021-08-24 Interventional | 1/2 | 6 | Gallium 68 PSMA… Pluvicto Prostatic Neopl… Prostate Cancer | Sponsor withdrawal The study was terminated early due to sponsor withdrawal (PSMA-617 no longer available for purchase). | |||
| NCT00041691 Details | 2021-08-19 Interventional | 1 | - | Labetuzumab Colorectal Neop… | - - | |||
| NCT04430933 Details | 2021-08-18 Interventional | 1/2 | 0 | Carboplatin Docetaxel Paclitaxel Pemetrexed Carcinoma, Non-… Lung Neoplasms Advanced or Met… Non-Small Cell … | Upon reviewing current available combo studies, the sponsor decided to prioritize different
combo study. - | |||
| NCT03352414 Details | 2021-08-18 Interventional | 2 | 84 | Alvimopan Ileus | stopped by sponsor - | |||
| NCT00644878 Details | 2021-08-18 Interventional | 2 | 18 | Nilotinib Leukemia Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Philadelphia Ch… Chronic Myeloge… | Slower than expected enrollment The study was terminated on 31 March 2012 due to slower than planned enrollment, resulting in a small sample size, no inferential analyses were conducted. | |||
| NCT00881556 Details | 2021-08-17 Interventional | 1 | 3 | Alemtuzumab Busulfan Fludarabine Lorazepam Tacrolimus Epidermolysis B… Epidermolysis B… | - - |